nodes	percent_of_prediction	percent_of_DWPC	metapath
Midazolam—CYP3A4—bone cancer	0.667	1	CbGaD
Midazolam—Skin necrosis—Epirubicin—bone cancer	0.00242	0.0134	CcSEcCtD
Midazolam—Skin necrosis—Doxorubicin—bone cancer	0.00224	0.0124	CcSEcCtD
Midazolam—Rhinorrhoea—Cisplatin—bone cancer	0.00203	0.0112	CcSEcCtD
Midazolam—Tenderness—Cisplatin—bone cancer	0.00189	0.0104	CcSEcCtD
Midazolam—Dysarthria—Cisplatin—bone cancer	0.00174	0.00962	CcSEcCtD
Midazolam—Pain—Carboplatin—bone cancer	0.00171	0.00947	CcSEcCtD
Midazolam—Hiccups—Cisplatin—bone cancer	0.00165	0.0091	CcSEcCtD
Midazolam—Wheezing—Cisplatin—bone cancer	0.0016	0.00884	CcSEcCtD
Midazolam—Skin exfoliation—Cisplatin—bone cancer	0.00157	0.00869	CcSEcCtD
Midazolam—Fracture—Methotrexate—bone cancer	0.00155	0.0086	CcSEcCtD
Midazolam—Multiple fractures—Methotrexate—bone cancer	0.00155	0.0086	CcSEcCtD
Midazolam—Local reaction—Epirubicin—bone cancer	0.00153	0.00844	CcSEcCtD
Midazolam—Hypoxia—Methotrexate—bone cancer	0.00142	0.00786	CcSEcCtD
Midazolam—Local reaction—Doxorubicin—bone cancer	0.00141	0.00781	CcSEcCtD
Midazolam—Phlebitis—Cisplatin—bone cancer	0.00139	0.00767	CcSEcCtD
Midazolam—Redness—Epirubicin—bone cancer	0.00125	0.00692	CcSEcCtD
Midazolam—Anaphylactoid reaction—Cisplatin—bone cancer	0.00123	0.00683	CcSEcCtD
Midazolam—Hyperventilation—Epirubicin—bone cancer	0.00123	0.00679	CcSEcCtD
Midazolam—Thrombosis—Epirubicin—bone cancer	0.00119	0.0066	CcSEcCtD
Midazolam—Nystagmus—Epirubicin—bone cancer	0.00118	0.00654	CcSEcCtD
Midazolam—Redness—Doxorubicin—bone cancer	0.00116	0.00641	CcSEcCtD
Midazolam—Irritability—Cisplatin—bone cancer	0.00114	0.00631	CcSEcCtD
Midazolam—Hyperventilation—Doxorubicin—bone cancer	0.00114	0.00629	CcSEcCtD
Midazolam—Thrombosis—Doxorubicin—bone cancer	0.00111	0.00611	CcSEcCtD
Midazolam—Nystagmus—Doxorubicin—bone cancer	0.0011	0.00606	CcSEcCtD
Midazolam—Feeling hot—Epirubicin—bone cancer	0.00108	0.00596	CcSEcCtD
Midazolam—Nasopharyngitis—Cisplatin—bone cancer	0.00107	0.00591	CcSEcCtD
Midazolam—Apnoea—Methotrexate—bone cancer	0.00107	0.00589	CcSEcCtD
Midazolam—Injection site pain—Epirubicin—bone cancer	0.00104	0.00573	CcSEcCtD
Midazolam—Dysphonia—Epirubicin—bone cancer	0.00103	0.00568	CcSEcCtD
Midazolam—Musculoskeletal stiffness—Methotrexate—bone cancer	0.00101	0.00557	CcSEcCtD
Midazolam—Feeling hot—Doxorubicin—bone cancer	0.000997	0.00551	CcSEcCtD
Midazolam—Delirium—Epirubicin—bone cancer	0.000983	0.00544	CcSEcCtD
Midazolam—Injection site pain—Doxorubicin—bone cancer	0.000958	0.0053	CcSEcCtD
Midazolam—Dysarthria—Methotrexate—bone cancer	0.000955	0.00528	CcSEcCtD
Midazolam—Dysphonia—Doxorubicin—bone cancer	0.000951	0.00526	CcSEcCtD
Midazolam—Ventricular extrasystoles—Epirubicin—bone cancer	0.000936	0.00518	CcSEcCtD
Midazolam—Respiratory failure—Methotrexate—bone cancer	0.00092	0.00509	CcSEcCtD
Midazolam—Delirium—Doxorubicin—bone cancer	0.00091	0.00503	CcSEcCtD
Midazolam—Neuropathy peripheral—Cisplatin—bone cancer	0.000903	0.00499	CcSEcCtD
Midazolam—Dyskinesia—Epirubicin—bone cancer	0.0009	0.00497	CcSEcCtD
Midazolam—Dysarthria—Epirubicin—bone cancer	0.000894	0.00494	CcSEcCtD
Midazolam—Depressed level of consciousness—Methotrexate—bone cancer	0.000872	0.00482	CcSEcCtD
Midazolam—Ventricular extrasystoles—Doxorubicin—bone cancer	0.000866	0.00479	CcSEcCtD
Midazolam—Skin exfoliation—Methotrexate—bone cancer	0.000863	0.00477	CcSEcCtD
Midazolam—Ventricular tachycardia—Epirubicin—bone cancer	0.000846	0.00468	CcSEcCtD
Midazolam—Hiccups—Epirubicin—bone cancer	0.000846	0.00468	CcSEcCtD
Midazolam—Bradycardia—Cisplatin—bone cancer	0.000842	0.00465	CcSEcCtD
Midazolam—Dyskinesia—Doxorubicin—bone cancer	0.000833	0.0046	CcSEcCtD
Midazolam—Dysarthria—Doxorubicin—bone cancer	0.000827	0.00457	CcSEcCtD
Midazolam—Salivary hypersecretion—Epirubicin—bone cancer	0.000821	0.00454	CcSEcCtD
Midazolam—Connective tissue disorder—Cisplatin—bone cancer	0.000813	0.00449	CcSEcCtD
Midazolam—Skin exfoliation—Epirubicin—bone cancer	0.000807	0.00446	CcSEcCtD
Midazolam—Visual impairment—Cisplatin—bone cancer	0.000797	0.00441	CcSEcCtD
Midazolam—Ventricular tachycardia—Doxorubicin—bone cancer	0.000782	0.00433	CcSEcCtD
Midazolam—Hiccups—Doxorubicin—bone cancer	0.000782	0.00433	CcSEcCtD
Midazolam—Eye disorder—Cisplatin—bone cancer	0.000773	0.00427	CcSEcCtD
Midazolam—Cardiac disorder—Cisplatin—bone cancer	0.000767	0.00424	CcSEcCtD
Midazolam—Salivary hypersecretion—Doxorubicin—bone cancer	0.00076	0.0042	CcSEcCtD
Midazolam—Thrombophlebitis—Methotrexate—bone cancer	0.000758	0.00419	CcSEcCtD
Midazolam—Skin exfoliation—Doxorubicin—bone cancer	0.000747	0.00413	CcSEcCtD
Midazolam—Immune system disorder—Cisplatin—bone cancer	0.000747	0.00413	CcSEcCtD
Midazolam—Mediastinal disorder—Cisplatin—bone cancer	0.000745	0.00412	CcSEcCtD
Midazolam—Ketazolam—CYP3A4—bone cancer	0.000735	0.09	CrCbGaD
Midazolam—Erythema—Cisplatin—bone cancer	0.00072	0.00398	CcSEcCtD
Midazolam—Phlebitis—Epirubicin—bone cancer	0.000712	0.00394	CcSEcCtD
Midazolam—Thrombophlebitis—Epirubicin—bone cancer	0.000709	0.00392	CcSEcCtD
Midazolam—Visual disturbance—Methotrexate—bone cancer	0.000692	0.00383	CcSEcCtD
Midazolam—Vision blurred—Cisplatin—bone cancer	0.000678	0.00375	CcSEcCtD
Midazolam—Anaphylactoid reaction—Methotrexate—bone cancer	0.000678	0.00375	CcSEcCtD
Midazolam—Tremor—Cisplatin—bone cancer	0.000674	0.00373	CcSEcCtD
Midazolam—Lethargy—Methotrexate—bone cancer	0.000669	0.0037	CcSEcCtD
Midazolam—Phlebitis—Doxorubicin—bone cancer	0.000659	0.00364	CcSEcCtD
Midazolam—Thrombophlebitis—Doxorubicin—bone cancer	0.000656	0.00363	CcSEcCtD
Midazolam—Osteoarthritis—Methotrexate—bone cancer	0.000656	0.00363	CcSEcCtD
Midazolam—Anaphylactoid reaction—Epirubicin—bone cancer	0.000634	0.00351	CcSEcCtD
Midazolam—Cardiac failure—Epirubicin—bone cancer	0.000629	0.00348	CcSEcCtD
Midazolam—Lethargy—Epirubicin—bone cancer	0.000626	0.00346	CcSEcCtD
Midazolam—Irritability—Methotrexate—bone cancer	0.000626	0.00346	CcSEcCtD
Midazolam—Mood swings—Methotrexate—bone cancer	0.000621	0.00344	CcSEcCtD
Midazolam—Ataxia—Methotrexate—bone cancer	0.000617	0.00341	CcSEcCtD
Midazolam—Osteoarthritis—Epirubicin—bone cancer	0.000614	0.00339	CcSEcCtD
Midazolam—Diplopia—Epirubicin—bone cancer	0.000614	0.00339	CcSEcCtD
Midazolam—Chlordiazepoxide—CYP3A4—bone cancer	0.000613	0.0752	CrCbGaD
Midazolam—Anxiety—Cisplatin—bone cancer	0.000611	0.00338	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000609	0.00336	CcSEcCtD
Midazolam—Affect lability—Epirubicin—bone cancer	0.000604	0.00334	CcSEcCtD
Midazolam—Clonazepam—CYP3A4—bone cancer	0.000592	0.0726	CrCbGaD
Midazolam—Anaphylactic shock—Cisplatin—bone cancer	0.000587	0.00325	CcSEcCtD
Midazolam—Anaphylactoid reaction—Doxorubicin—bone cancer	0.000587	0.00324	CcSEcCtD
Midazolam—Cardiac arrest—Epirubicin—bone cancer	0.000584	0.00323	CcSEcCtD
Midazolam—Cardiac failure—Doxorubicin—bone cancer	0.000582	0.00322	CcSEcCtD
Midazolam—Mood swings—Epirubicin—bone cancer	0.000581	0.00321	CcSEcCtD
Midazolam—Lethargy—Doxorubicin—bone cancer	0.00058	0.0032	CcSEcCtD
Midazolam—Ataxia—Epirubicin—bone cancer	0.000577	0.00319	CcSEcCtD
Midazolam—Nervous system disorder—Cisplatin—bone cancer	0.000576	0.00319	CcSEcCtD
Midazolam—Clorazepate—CYP3A4—bone cancer	0.000573	0.0703	CrCbGaD
Midazolam—Tachycardia—Cisplatin—bone cancer	0.000573	0.00317	CcSEcCtD
Midazolam—Skin disorder—Cisplatin—bone cancer	0.000571	0.00315	CcSEcCtD
Midazolam—Diplopia—Doxorubicin—bone cancer	0.000568	0.00314	CcSEcCtD
Midazolam—Osteoarthritis—Doxorubicin—bone cancer	0.000568	0.00314	CcSEcCtD
Midazolam—Affect lability—Doxorubicin—bone cancer	0.000559	0.00309	CcSEcCtD
Midazolam—Clotiazepam—CYP3A4—bone cancer	0.00055	0.0674	CrCbGaD
Midazolam—Hypotension—Cisplatin—bone cancer	0.000549	0.00303	CcSEcCtD
Midazolam—Nasopharyngitis—Epirubicin—bone cancer	0.000549	0.00303	CcSEcCtD
Midazolam—Muscular weakness—Epirubicin—bone cancer	0.000541	0.00299	CcSEcCtD
Midazolam—Cardiac arrest—Doxorubicin—bone cancer	0.00054	0.00299	CcSEcCtD
Midazolam—Mood swings—Doxorubicin—bone cancer	0.000538	0.00297	CcSEcCtD
Midazolam—Ataxia—Doxorubicin—bone cancer	0.000534	0.00295	CcSEcCtD
Midazolam—Paraesthesia—Cisplatin—bone cancer	0.000528	0.00292	CcSEcCtD
Midazolam—Dyspnoea—Cisplatin—bone cancer	0.000524	0.0029	CcSEcCtD
Midazolam—Clobazam—CYP3A4—bone cancer	0.000519	0.0636	CrCbGaD
Midazolam—Alprazolam—CYP3A4—bone cancer	0.000519	0.0636	CrCbGaD
Midazolam—Nasopharyngitis—Doxorubicin—bone cancer	0.000508	0.00281	CcSEcCtD
Midazolam—Gastrointestinal disorder—Cisplatin—bone cancer	0.000507	0.0028	CcSEcCtD
Midazolam—Drowsiness—Methotrexate—bone cancer	0.000505	0.00279	CcSEcCtD
Midazolam—Depression—Methotrexate—bone cancer	0.000504	0.00279	CcSEcCtD
Midazolam—Quazepam—CYP3A4—bone cancer	0.000503	0.0617	CrCbGaD
Midazolam—Pain—Cisplatin—bone cancer	0.000502	0.00278	CcSEcCtD
Midazolam—Muscular weakness—Doxorubicin—bone cancer	0.000501	0.00277	CcSEcCtD
Midazolam—Feeling abnormal—Cisplatin—bone cancer	0.000484	0.00268	CcSEcCtD
Midazolam—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000477	0.00332	CbGpPWpGaD
Midazolam—Flunitrazepam—CYP3A4—bone cancer	0.000475	0.0583	CrCbGaD
Midazolam—CYP2E1—Tryptophan metabolism—CYP3A4—bone cancer	0.000473	0.0033	CbGpPWpGaD
Midazolam—Drowsiness—Epirubicin—bone cancer	0.000473	0.00262	CcSEcCtD
Midazolam—UGT1A4—Biological oxidations—CYP3A4—bone cancer	0.000471	0.00328	CbGpPWpGaD
Midazolam—UGT1A4—Metapathway biotransformation—CYP3A4—bone cancer	0.000465	0.00324	CbGpPWpGaD
Midazolam—Neuropathy peripheral—Epirubicin—bone cancer	0.000464	0.00256	CcSEcCtD
Midazolam—UGT1A4—NRF2 pathway—TGFBR2—bone cancer	0.000459	0.0032	CbGpPWpGaD
Midazolam—UGT1A4—NRF2 pathway—GSTP1—bone cancer	0.000459	0.0032	CbGpPWpGaD
Midazolam—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000454	0.00316	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—NDUFA12—bone cancer	0.000451	0.00314	CbGpPWpGaD
Midazolam—Estazolam—CYP3A4—bone cancer	0.000445	0.0545	CrCbGaD
Midazolam—Drowsiness—Doxorubicin—bone cancer	0.000438	0.00242	CcSEcCtD
Midazolam—Visual impairment—Methotrexate—bone cancer	0.000437	0.00242	CcSEcCtD
Midazolam—Hypersensitivity—Cisplatin—bone cancer	0.000433	0.00239	CcSEcCtD
Midazolam—Bradycardia—Epirubicin—bone cancer	0.000432	0.00239	CcSEcCtD
Midazolam—Neuropathy peripheral—Doxorubicin—bone cancer	0.000429	0.00237	CcSEcCtD
Midazolam—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000428	0.00298	CbGpPWpGaD
Midazolam—UGT1A4—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000425	0.00296	CbGpPWpGaD
Midazolam—Eye disorder—Methotrexate—bone cancer	0.000424	0.00234	CcSEcCtD
Midazolam—Adinazolam—CYP3A4—bone cancer	0.000423	0.0519	CrCbGaD
Midazolam—Asthenia—Cisplatin—bone cancer	0.000421	0.00233	CcSEcCtD
Midazolam—Cardiac disorder—Methotrexate—bone cancer	0.000421	0.00233	CcSEcCtD
Midazolam—GABRB3—BDNF signaling pathway—EIF2S1—bone cancer	0.00042	0.00293	CbGpPWpGaD
Midazolam—Connective tissue disorder—Epirubicin—bone cancer	0.000417	0.00231	CcSEcCtD
Midazolam—Immune system disorder—Methotrexate—bone cancer	0.00041	0.00227	CcSEcCtD
Midazolam—Prazepam—CYP3A4—bone cancer	0.000409	0.0502	CrCbGaD
Midazolam—Visual impairment—Epirubicin—bone cancer	0.000409	0.00226	CcSEcCtD
Midazolam—Mediastinal disorder—Methotrexate—bone cancer	0.000409	0.00226	CcSEcCtD
Midazolam—Chills—Methotrexate—bone cancer	0.000407	0.00225	CcSEcCtD
Midazolam—UGT1A4—Biological oxidations—GSTP1—bone cancer	0.000403	0.00281	CbGpPWpGaD
Midazolam—Bradycardia—Doxorubicin—bone cancer	0.0004	0.00221	CcSEcCtD
Midazolam—Mental disorder—Methotrexate—bone cancer	0.000398	0.0022	CcSEcCtD
Midazolam—UGT1A4—Metapathway biotransformation—GSTP1—bone cancer	0.000397	0.00277	CbGpPWpGaD
Midazolam—Eye disorder—Epirubicin—bone cancer	0.000397	0.00219	CcSEcCtD
Midazolam—Erythema—Methotrexate—bone cancer	0.000395	0.00218	CcSEcCtD
Midazolam—Cardiac disorder—Epirubicin—bone cancer	0.000394	0.00218	CcSEcCtD
Midazolam—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000391	0.00272	CbGpPWpGaD
Midazolam—Connective tissue disorder—Doxorubicin—bone cancer	0.000386	0.00213	CcSEcCtD
Midazolam—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000386	0.00269	CbGpPWpGaD
Midazolam—Immune system disorder—Epirubicin—bone cancer	0.000384	0.00212	CcSEcCtD
Midazolam—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000383	0.00267	CbGpPWpGaD
Midazolam—Mediastinal disorder—Epirubicin—bone cancer	0.000383	0.00212	CcSEcCtD
Midazolam—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000382	0.00266	CbGpPWpGaD
Midazolam—Flurazepam—CYP3A4—bone cancer	0.000382	0.0468	CrCbGaD
Midazolam—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000381	0.00266	CbGpPWpGaD
Midazolam—Triazolam—CYP3A4—bone cancer	0.000381	0.0467	CrCbGaD
Midazolam—Chills—Epirubicin—bone cancer	0.000381	0.00211	CcSEcCtD
Midazolam—Visual impairment—Doxorubicin—bone cancer	0.000379	0.00209	CcSEcCtD
Midazolam—CYP2E1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000378	0.00263	CbGpPWpGaD
Midazolam—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000377	0.00263	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—NT5C3A—bone cancer	0.000374	0.00261	CbGpPWpGaD
Midazolam—Vomiting—Cisplatin—bone cancer	0.000374	0.00206	CcSEcCtD
Midazolam—Vision blurred—Methotrexate—bone cancer	0.000372	0.00206	CcSEcCtD
Midazolam—Mental disorder—Epirubicin—bone cancer	0.000372	0.00206	CcSEcCtD
Midazolam—Rash—Cisplatin—bone cancer	0.00037	0.00205	CcSEcCtD
Midazolam—Dermatitis—Cisplatin—bone cancer	0.00037	0.00205	CcSEcCtD
Midazolam—Erythema—Epirubicin—bone cancer	0.00037	0.00204	CcSEcCtD
Midazolam—Oxazepam—CYP3A4—bone cancer	0.00037	0.0453	CrCbGaD
Midazolam—Eye disorder—Doxorubicin—bone cancer	0.000367	0.00203	CcSEcCtD
Midazolam—Temazepam—CYP3A4—bone cancer	0.000365	0.0447	CrCbGaD
Midazolam—Cardiac disorder—Doxorubicin—bone cancer	0.000365	0.00202	CcSEcCtD
Midazolam—Tension—Epirubicin—bone cancer	0.000363	0.00201	CcSEcCtD
Midazolam—Nervousness—Epirubicin—bone cancer	0.000359	0.00198	CcSEcCtD
Midazolam—GABRR1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000359	0.0025	CbGpPWpGaD
Midazolam—Immune system disorder—Doxorubicin—bone cancer	0.000355	0.00196	CcSEcCtD
Midazolam—Vertigo—Methotrexate—bone cancer	0.000355	0.00196	CcSEcCtD
Midazolam—Mediastinal disorder—Doxorubicin—bone cancer	0.000354	0.00196	CcSEcCtD
Midazolam—Chills—Doxorubicin—bone cancer	0.000353	0.00195	CcSEcCtD
Midazolam—Nausea—Cisplatin—bone cancer	0.000349	0.00193	CcSEcCtD
Midazolam—Vision blurred—Epirubicin—bone cancer	0.000348	0.00193	CcSEcCtD
Midazolam—Cough—Methotrexate—bone cancer	0.000345	0.00191	CcSEcCtD
Midazolam—Mental disorder—Doxorubicin—bone cancer	0.000344	0.0019	CcSEcCtD
Midazolam—GABRR2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000342	0.00239	CbGpPWpGaD
Midazolam—GABRQ—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000342	0.00239	CbGpPWpGaD
Midazolam—Erythema—Doxorubicin—bone cancer	0.000342	0.00189	CcSEcCtD
Midazolam—Agitation—Epirubicin—bone cancer	0.00034	0.00188	CcSEcCtD
Midazolam—Tension—Doxorubicin—bone cancer	0.000336	0.00186	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000334	0.00185	CcSEcCtD
Midazolam—Nervousness—Doxorubicin—bone cancer	0.000332	0.00184	CcSEcCtD
Midazolam—Vertigo—Epirubicin—bone cancer	0.000332	0.00184	CcSEcCtD
Midazolam—Syncope—Epirubicin—bone cancer	0.000331	0.00183	CcSEcCtD
Midazolam—Confusional state—Methotrexate—bone cancer	0.000325	0.0018	CcSEcCtD
Midazolam—Cough—Epirubicin—bone cancer	0.000323	0.00178	CcSEcCtD
Midazolam—Anaphylactic shock—Methotrexate—bone cancer	0.000322	0.00178	CcSEcCtD
Midazolam—Vision blurred—Doxorubicin—bone cancer	0.000322	0.00178	CcSEcCtD
Midazolam—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000317	0.00221	CbGpPWpGaD
Midazolam—Nervous system disorder—Methotrexate—bone cancer	0.000316	0.00175	CcSEcCtD
Midazolam—Agitation—Doxorubicin—bone cancer	0.000314	0.00174	CcSEcCtD
Midazolam—Anxiety—Epirubicin—bone cancer	0.000314	0.00173	CcSEcCtD
Midazolam—Skin disorder—Methotrexate—bone cancer	0.000313	0.00173	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000313	0.00173	CcSEcCtD
Midazolam—CYP2E1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00031	0.00216	CbGpPWpGaD
Midazolam—GABRR1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00031	0.00216	CbGpPWpGaD
Midazolam—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00031	0.00216	CbGpPWpGaD
Midazolam—Dry mouth—Epirubicin—bone cancer	0.000308	0.0017	CcSEcCtD
Midazolam—Vertigo—Doxorubicin—bone cancer	0.000307	0.0017	CcSEcCtD
Midazolam—Syncope—Doxorubicin—bone cancer	0.000307	0.0017	CcSEcCtD
Midazolam—Confusional state—Epirubicin—bone cancer	0.000304	0.00168	CcSEcCtD
Midazolam—Diazepam—CYP3A4—bone cancer	0.000303	0.0372	CrCbGaD
Midazolam—GABRR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000303	0.00211	CbGpPWpGaD
Midazolam—Anaphylactic shock—Epirubicin—bone cancer	0.000302	0.00167	CcSEcCtD
Midazolam—Hypotension—Methotrexate—bone cancer	0.000301	0.00167	CcSEcCtD
Midazolam—Cough—Doxorubicin—bone cancer	0.000298	0.00165	CcSEcCtD
Midazolam—Shock—Epirubicin—bone cancer	0.000297	0.00164	CcSEcCtD
Midazolam—Nervous system disorder—Epirubicin—bone cancer	0.000296	0.00164	CcSEcCtD
Midazolam—GABRR2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000296	0.00206	CbGpPWpGaD
Midazolam—GABRQ—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000296	0.00206	CbGpPWpGaD
Midazolam—Tachycardia—Epirubicin—bone cancer	0.000294	0.00163	CcSEcCtD
Midazolam—Skin disorder—Epirubicin—bone cancer	0.000293	0.00162	CcSEcCtD
Midazolam—Anxiety—Doxorubicin—bone cancer	0.00029	0.0016	CcSEcCtD
Midazolam—Paraesthesia—Methotrexate—bone cancer	0.000289	0.0016	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000289	0.0016	CcSEcCtD
Midazolam—GABRR2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000289	0.00201	CbGpPWpGaD
Midazolam—GABRQ—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000289	0.00201	CbGpPWpGaD
Midazolam—Dyspnoea—Methotrexate—bone cancer	0.000287	0.00159	CcSEcCtD
Midazolam—Somnolence—Methotrexate—bone cancer	0.000287	0.00158	CcSEcCtD
Midazolam—Dry mouth—Doxorubicin—bone cancer	0.000285	0.00157	CcSEcCtD
Midazolam—Dyspepsia—Methotrexate—bone cancer	0.000284	0.00157	CcSEcCtD
Midazolam—UGT1A4—Metabolism—NDUFA12—bone cancer	0.000282	0.00197	CbGpPWpGaD
Midazolam—GABRG3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000282	0.00196	CbGpPWpGaD
Midazolam—Hypotension—Epirubicin—bone cancer	0.000282	0.00156	CcSEcCtD
Midazolam—Confusional state—Doxorubicin—bone cancer	0.000281	0.00156	CcSEcCtD
Midazolam—Anaphylactic shock—Doxorubicin—bone cancer	0.000279	0.00154	CcSEcCtD
Midazolam—Gastrointestinal disorder—Methotrexate—bone cancer	0.000278	0.00154	CcSEcCtD
Midazolam—Fatigue—Methotrexate—bone cancer	0.000278	0.00154	CcSEcCtD
Midazolam—GABRB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000278	0.00193	CbGpPWpGaD
Midazolam—Pain—Methotrexate—bone cancer	0.000276	0.00152	CcSEcCtD
Midazolam—Shock—Doxorubicin—bone cancer	0.000275	0.00152	CcSEcCtD
Midazolam—Nervous system disorder—Doxorubicin—bone cancer	0.000274	0.00151	CcSEcCtD
Midazolam—Tachycardia—Doxorubicin—bone cancer	0.000272	0.00151	CcSEcCtD
Midazolam—Skin disorder—Doxorubicin—bone cancer	0.000271	0.0015	CcSEcCtD
Midazolam—Paraesthesia—Epirubicin—bone cancer	0.000271	0.0015	CcSEcCtD
Midazolam—Dyspnoea—Epirubicin—bone cancer	0.000269	0.00149	CcSEcCtD
Midazolam—Somnolence—Epirubicin—bone cancer	0.000268	0.00148	CcSEcCtD
Midazolam—Feeling abnormal—Methotrexate—bone cancer	0.000266	0.00147	CcSEcCtD
Midazolam—Dyspepsia—Epirubicin—bone cancer	0.000266	0.00147	CcSEcCtD
Midazolam—GABRA6—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000263	0.00183	CbGpPWpGaD
Midazolam—Hypotension—Doxorubicin—bone cancer	0.000261	0.00144	CcSEcCtD
Midazolam—Gastrointestinal disorder—Epirubicin—bone cancer	0.00026	0.00144	CcSEcCtD
Midazolam—Fatigue—Epirubicin—bone cancer	0.00026	0.00144	CcSEcCtD
Midazolam—GABRA4—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000259	0.00181	CbGpPWpGaD
Midazolam—Constipation—Epirubicin—bone cancer	0.000258	0.00143	CcSEcCtD
Midazolam—Pain—Epirubicin—bone cancer	0.000258	0.00143	CcSEcCtD
Midazolam—Urticaria—Methotrexate—bone cancer	0.000256	0.00142	CcSEcCtD
Midazolam—GABRR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000254	0.00177	CbGpPWpGaD
Midazolam—Paraesthesia—Doxorubicin—bone cancer	0.000251	0.00139	CcSEcCtD
Midazolam—Dyspnoea—Doxorubicin—bone cancer	0.000249	0.00138	CcSEcCtD
Midazolam—Feeling abnormal—Epirubicin—bone cancer	0.000249	0.00137	CcSEcCtD
Midazolam—Somnolence—Doxorubicin—bone cancer	0.000248	0.00137	CcSEcCtD
Midazolam—Dyspepsia—Doxorubicin—bone cancer	0.000246	0.00136	CcSEcCtD
Midazolam—GABRG3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000243	0.0017	CbGpPWpGaD
Midazolam—GABRR2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000242	0.00169	CbGpPWpGaD
Midazolam—GABRQ—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000242	0.00169	CbGpPWpGaD
Midazolam—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000241	0.00133	CcSEcCtD
Midazolam—Fatigue—Doxorubicin—bone cancer	0.000241	0.00133	CcSEcCtD
Midazolam—GABRB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00024	0.00167	CbGpPWpGaD
Midazolam—Urticaria—Epirubicin—bone cancer	0.00024	0.00132	CcSEcCtD
Midazolam—Pain—Doxorubicin—bone cancer	0.000239	0.00132	CcSEcCtD
Midazolam—Constipation—Doxorubicin—bone cancer	0.000239	0.00132	CcSEcCtD
Midazolam—GABRG3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000238	0.00166	CbGpPWpGaD
Midazolam—Hypersensitivity—Methotrexate—bone cancer	0.000238	0.00131	CcSEcCtD
Midazolam—GABRB2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000237	0.00165	CbGpPWpGaD
Midazolam—GABRB1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000234	0.00163	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—NT5C3A—bone cancer	0.000234	0.00163	CbGpPWpGaD
Midazolam—Asthenia—Methotrexate—bone cancer	0.000231	0.00128	CcSEcCtD
Midazolam—GABRA5—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000231	0.00161	CbGpPWpGaD
Midazolam—Feeling abnormal—Doxorubicin—bone cancer	0.00023	0.00127	CcSEcCtD
Midazolam—Pruritus—Methotrexate—bone cancer	0.000228	0.00126	CcSEcCtD
Midazolam—GABRR1—Transmission across Chemical Synapses—BRAF—bone cancer	0.000228	0.00159	CbGpPWpGaD
Midazolam—CYP3A7—Biological oxidations—CYP3A4—bone cancer	0.000228	0.00159	CbGpPWpGaD
Midazolam—GABRA6—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000227	0.00158	CbGpPWpGaD
Midazolam—GABRA3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000226	0.00158	CbGpPWpGaD
Midazolam—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	0.000224	0.00156	CbGpPWpGaD
Midazolam—GABRA4—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000224	0.00156	CbGpPWpGaD
Midazolam—GABRA2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000223	0.00155	CbGpPWpGaD
Midazolam—Hypersensitivity—Epirubicin—bone cancer	0.000222	0.00123	CcSEcCtD
Midazolam—Urticaria—Doxorubicin—bone cancer	0.000222	0.00123	CcSEcCtD
Midazolam—GABRA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000222	0.00154	CbGpPWpGaD
Midazolam—GABRB3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000221	0.00154	CbGpPWpGaD
Midazolam—GABRA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000219	0.00152	CbGpPWpGaD
Midazolam—CYP2E1—Tryptophan metabolism—MDM2—bone cancer	0.000218	0.00152	CbGpPWpGaD
Midazolam—GABRQ—Transmission across Chemical Synapses—BRAF—bone cancer	0.000217	0.00151	CbGpPWpGaD
Midazolam—GABRR2—Transmission across Chemical Synapses—BRAF—bone cancer	0.000217	0.00151	CbGpPWpGaD
Midazolam—GABRG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000217	0.00151	CbGpPWpGaD
Midazolam—Asthenia—Epirubicin—bone cancer	0.000216	0.0012	CcSEcCtD
Midazolam—Pruritus—Epirubicin—bone cancer	0.000213	0.00118	CcSEcCtD
Midazolam—Dizziness—Methotrexate—bone cancer	0.000213	0.00118	CcSEcCtD
Midazolam—Hypersensitivity—Doxorubicin—bone cancer	0.000206	0.00114	CcSEcCtD
Midazolam—Vomiting—Methotrexate—bone cancer	0.000205	0.00113	CcSEcCtD
Midazolam—GABRB2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000205	0.00143	CbGpPWpGaD
Midazolam—Rash—Methotrexate—bone cancer	0.000203	0.00112	CcSEcCtD
Midazolam—Dermatitis—Methotrexate—bone cancer	0.000203	0.00112	CcSEcCtD
Midazolam—Headache—Methotrexate—bone cancer	0.000202	0.00112	CcSEcCtD
Midazolam—Asthenia—Doxorubicin—bone cancer	0.0002	0.00111	CcSEcCtD
Midazolam—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.0002	0.00139	CbGpPWpGaD
Midazolam—Dizziness—Epirubicin—bone cancer	0.000199	0.0011	CcSEcCtD
Midazolam—GABRG3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000199	0.00139	CbGpPWpGaD
Midazolam—GABRA5—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000199	0.00139	CbGpPWpGaD
Midazolam—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000198	0.00138	CbGpPWpGaD
Midazolam—Pruritus—Doxorubicin—bone cancer	0.000197	0.00109	CcSEcCtD
Midazolam—GABRB1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000196	0.00137	CbGpPWpGaD
Midazolam—GABRA3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000195	0.00136	CbGpPWpGaD
Midazolam—CYP3A7—Biological oxidations—GSTP1—bone cancer	0.000195	0.00136	CbGpPWpGaD
Midazolam—GABRA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000195	0.00136	CbGpPWpGaD
Midazolam—GABRA2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000192	0.00134	CbGpPWpGaD
Midazolam—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	0.000192	0.00134	CbGpPWpGaD
Midazolam—Vomiting—Epirubicin—bone cancer	0.000192	0.00106	CcSEcCtD
Midazolam—Nausea—Methotrexate—bone cancer	0.000191	0.00106	CcSEcCtD
Midazolam—GABRA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000191	0.00133	CbGpPWpGaD
Midazolam—GABRB3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000191	0.00133	CbGpPWpGaD
Midazolam—GABRR1—Transmission across Chemical Synapses—MDM2—bone cancer	0.000191	0.00133	CbGpPWpGaD
Midazolam—Rash—Epirubicin—bone cancer	0.00019	0.00105	CcSEcCtD
Midazolam—Dermatitis—Epirubicin—bone cancer	0.00019	0.00105	CcSEcCtD
Midazolam—GABRA1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00019	0.00132	CbGpPWpGaD
Midazolam—Headache—Epirubicin—bone cancer	0.000189	0.00104	CcSEcCtD
Midazolam—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000188	0.00131	CbGpPWpGaD
Midazolam—GABRG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000187	0.00131	CbGpPWpGaD
Midazolam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000186	0.0013	CbGpPWpGaD
Midazolam—GABRA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000186	0.00129	CbGpPWpGaD
Midazolam—Dizziness—Doxorubicin—bone cancer	0.000185	0.00102	CcSEcCtD
Midazolam—GABRA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000183	0.00128	CbGpPWpGaD
Midazolam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000183	0.00128	CbGpPWpGaD
Midazolam—GABRQ—Transmission across Chemical Synapses—MDM2—bone cancer	0.000182	0.00127	CbGpPWpGaD
Midazolam—GABRR2—Transmission across Chemical Synapses—MDM2—bone cancer	0.000182	0.00127	CbGpPWpGaD
Midazolam—Nausea—Epirubicin—bone cancer	0.000179	0.000991	CcSEcCtD
Midazolam—GABRG3—Transmission across Chemical Synapses—BRAF—bone cancer	0.000179	0.00125	CbGpPWpGaD
Midazolam—Vomiting—Doxorubicin—bone cancer	0.000177	0.000981	CcSEcCtD
Midazolam—GABRB1—Transmission across Chemical Synapses—BRAF—bone cancer	0.000176	0.00123	CbGpPWpGaD
Midazolam—Rash—Doxorubicin—bone cancer	0.000176	0.000973	CcSEcCtD
Midazolam—Dermatitis—Doxorubicin—bone cancer	0.000176	0.000972	CcSEcCtD
Midazolam—Headache—Doxorubicin—bone cancer	0.000175	0.000967	CcSEcCtD
Midazolam—GABRR1—Neuronal System—BRAF—bone cancer	0.000174	0.00121	CbGpPWpGaD
Midazolam—CYP2B6—Biological oxidations—CYP3A4—bone cancer	0.000168	0.00117	CbGpPWpGaD
Midazolam—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000168	0.00117	CbGpPWpGaD
Midazolam—GABRA6—Transmission across Chemical Synapses—BRAF—bone cancer	0.000167	0.00116	CbGpPWpGaD
Midazolam—GABRR2—Neuronal System—BRAF—bone cancer	0.000166	0.00116	CbGpPWpGaD
Midazolam—GABRQ—Neuronal System—BRAF—bone cancer	0.000166	0.00116	CbGpPWpGaD
Midazolam—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	0.000166	0.00116	CbGpPWpGaD
Midazolam—Nausea—Doxorubicin—bone cancer	0.000166	0.000917	CcSEcCtD
Midazolam—CYP2E1—Biological oxidations—CYP3A4—bone cancer	0.000165	0.00115	CbGpPWpGaD
Midazolam—GABRA4—Transmission across Chemical Synapses—BRAF—bone cancer	0.000165	0.00115	CbGpPWpGaD
Midazolam—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.000164	0.00115	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—ENO2—bone cancer	0.000164	0.00114	CbGpPWpGaD
Midazolam—GABRA1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000164	0.00114	CbGpPWpGaD
Midazolam—GABRA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000163	0.00114	CbGpPWpGaD
Midazolam—CYP2E1—Metapathway biotransformation—CYP3A4—bone cancer	0.000163	0.00113	CbGpPWpGaD
Midazolam—SLC22A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000162	0.00113	CbGpPWpGaD
Midazolam—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000162	0.00113	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000162	0.00113	CbGpPWpGaD
Midazolam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.00016	0.00112	CbGpPWpGaD
Midazolam—GABRA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.00016	0.00111	CbGpPWpGaD
Midazolam—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000157	0.0011	CbGpPWpGaD
Midazolam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000156	0.00109	CbGpPWpGaD
Midazolam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000153	0.00107	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—DHFR—bone cancer	0.000152	0.00106	CbGpPWpGaD
Midazolam—GABRB2—Transmission across Chemical Synapses—BRAF—bone cancer	0.000151	0.00105	CbGpPWpGaD
Midazolam—GABRG3—Transmission across Chemical Synapses—MDM2—bone cancer	0.00015	0.00104	CbGpPWpGaD
Midazolam—GABRB1—Transmission across Chemical Synapses—MDM2—bone cancer	0.000148	0.00103	CbGpPWpGaD
Midazolam—GABRA5—Transmission across Chemical Synapses—BRAF—bone cancer	0.000146	0.00102	CbGpPWpGaD
Midazolam—GABRR1—Neuronal System—MDM2—bone cancer	0.000146	0.00102	CbGpPWpGaD
Midazolam—CYP2B6—Biological oxidations—GSTP1—bone cancer	0.000144	0.001	CbGpPWpGaD
Midazolam—GABRA3—Transmission across Chemical Synapses—BRAF—bone cancer	0.000144	0.001	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—GNA11—bone cancer	0.000142	0.00099	CbGpPWpGaD
Midazolam—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	0.000142	0.000989	CbGpPWpGaD
Midazolam—GABRA2—Transmission across Chemical Synapses—BRAF—bone cancer	0.000141	0.000983	CbGpPWpGaD
Midazolam—CYP2E1—Biological oxidations—GSTP1—bone cancer	0.000141	0.000982	CbGpPWpGaD
Midazolam—CYP3A5—Biological oxidations—GSTP1—bone cancer	0.000141	0.00098	CbGpPWpGaD
Midazolam—GABRB3—Transmission across Chemical Synapses—BRAF—bone cancer	0.00014	0.000977	CbGpPWpGaD
Midazolam—SLC22A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00014	0.000976	CbGpPWpGaD
Midazolam—GABRA6—Transmission across Chemical Synapses—MDM2—bone cancer	0.00014	0.000973	CbGpPWpGaD
Midazolam—GABRR2—Neuronal System—MDM2—bone cancer	0.000139	0.000971	CbGpPWpGaD
Midazolam—GABRQ—Neuronal System—MDM2—bone cancer	0.000139	0.000971	CbGpPWpGaD
Midazolam—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	0.000139	0.000969	CbGpPWpGaD
Midazolam—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.000139	0.000967	CbGpPWpGaD
Midazolam—GABRA4—Transmission across Chemical Synapses—MDM2—bone cancer	0.000138	0.000961	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000138	0.000959	CbGpPWpGaD
Midazolam—GABRG2—Transmission across Chemical Synapses—BRAF—bone cancer	0.000138	0.000959	CbGpPWpGaD
Midazolam—GABRG3—Neuronal System—BRAF—bone cancer	0.000137	0.000954	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—NDUFA12—bone cancer	0.000136	0.00095	CbGpPWpGaD
Midazolam—GABRB1—Neuronal System—BRAF—bone cancer	0.000135	0.00094	CbGpPWpGaD
Midazolam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000134	0.000934	CbGpPWpGaD
Midazolam—GABRB3—BDNF signaling pathway—JUN—bone cancer	0.000133	0.000925	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—CYP3A4—bone cancer	0.000129	0.000897	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000128	0.000893	CbGpPWpGaD
Midazolam—GABRA6—Neuronal System—BRAF—bone cancer	0.000128	0.00089	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—NDUFA12—bone cancer	0.000127	0.000884	CbGpPWpGaD
Midazolam—GABRB2—Transmission across Chemical Synapses—MDM2—bone cancer	0.000126	0.000879	CbGpPWpGaD
Midazolam—GABRA4—Neuronal System—BRAF—bone cancer	0.000126	0.000878	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000125	0.000873	CbGpPWpGaD
Midazolam—GABRA5—Transmission across Chemical Synapses—MDM2—bone cancer	0.000123	0.000853	CbGpPWpGaD
Midazolam—GABRA1—Transmission across Chemical Synapses—BRAF—bone cancer	0.00012	0.000838	CbGpPWpGaD
Midazolam—GABRA3—Transmission across Chemical Synapses—MDM2—bone cancer	0.00012	0.000838	CbGpPWpGaD
Midazolam—GABRA2—Transmission across Chemical Synapses—MDM2—bone cancer	0.000118	0.000824	CbGpPWpGaD
Midazolam—GABRB3—Transmission across Chemical Synapses—MDM2—bone cancer	0.000117	0.000818	CbGpPWpGaD
Midazolam—GABRG2—Transmission across Chemical Synapses—MDM2—bone cancer	0.000115	0.000804	CbGpPWpGaD
Midazolam—GABRB2—Neuronal System—BRAF—bone cancer	0.000115	0.000803	CbGpPWpGaD
Midazolam—GABRG3—Neuronal System—MDM2—bone cancer	0.000115	0.0008	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000114	0.000795	CbGpPWpGaD
Midazolam—GABRB1—Neuronal System—MDM2—bone cancer	0.000113	0.000788	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—NT5C3A—bone cancer	0.000113	0.000787	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000113	0.000784	CbGpPWpGaD
Midazolam—GABRA5—Neuronal System—BRAF—bone cancer	0.000112	0.00078	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—GSTP1—bone cancer	0.00011	0.000767	CbGpPWpGaD
Midazolam—GABRA3—Neuronal System—BRAF—bone cancer	0.00011	0.000766	CbGpPWpGaD
Midazolam—GABRA2—Neuronal System—BRAF—bone cancer	0.000108	0.000753	CbGpPWpGaD
Midazolam—GABRB3—Neuronal System—BRAF—bone cancer	0.000107	0.000748	CbGpPWpGaD
Midazolam—GABRA6—Neuronal System—MDM2—bone cancer	0.000107	0.000745	CbGpPWpGaD
Midazolam—GABRA1—SIDS Susceptibility Pathways—JUN—bone cancer	0.000107	0.000745	CbGpPWpGaD
Midazolam—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000107	0.000743	CbGpPWpGaD
Midazolam—GABRA4—Neuronal System—MDM2—bone cancer	0.000106	0.000736	CbGpPWpGaD
Midazolam—GABRG2—Neuronal System—BRAF—bone cancer	0.000105	0.000735	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—NT5C3A—bone cancer	0.000105	0.000733	CbGpPWpGaD
Midazolam—SLC22A1—Transmission across Chemical Synapses—BRAF—bone cancer	0.000103	0.000717	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—ENO2—bone cancer	0.000102	0.000714	CbGpPWpGaD
Midazolam—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.000101	0.000703	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—NDUFA12—bone cancer	0.000101	0.000703	CbGpPWpGaD
Midazolam—GABRA1—Transmission across Chemical Synapses—MDM2—bone cancer	0.000101	0.000702	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—NDUFA12—bone cancer	9.88e-05	0.000688	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—NDUFA12—bone cancer	9.86e-05	0.000687	CbGpPWpGaD
Midazolam—GABRB2—Neuronal System—MDM2—bone cancer	9.66e-05	0.000673	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	9.54e-05	0.000665	CbGpPWpGaD
Midazolam—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.52e-05	0.000663	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—DHFR—bone cancer	9.51e-05	0.000662	CbGpPWpGaD
Midazolam—GABRA5—Neuronal System—MDM2—bone cancer	9.39e-05	0.000654	CbGpPWpGaD
Midazolam—GABRA1—Neuronal System—BRAF—bone cancer	9.22e-05	0.000642	CbGpPWpGaD
Midazolam—GABRA3—Neuronal System—MDM2—bone cancer	9.22e-05	0.000642	CbGpPWpGaD
Midazolam—GABRA2—Neuronal System—MDM2—bone cancer	9.06e-05	0.000631	CbGpPWpGaD
Midazolam—GABRB3—Neuronal System—MDM2—bone cancer	9e-05	0.000627	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—GNA11—bone cancer	8.89e-05	0.000619	CbGpPWpGaD
Midazolam—GABRG2—Neuronal System—MDM2—bone cancer	8.84e-05	0.000616	CbGpPWpGaD
Midazolam—SLC22A1—Transmission across Chemical Synapses—MDM2—bone cancer	8.63e-05	0.000601	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—NT5C3A—bone cancer	8.36e-05	0.000582	CbGpPWpGaD
Midazolam—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.22e-05	0.000572	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—NT5C3A—bone cancer	8.19e-05	0.00057	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—NT5C3A—bone cancer	8.17e-05	0.000569	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—CYP3A4—bone cancer	8.06e-05	0.000561	CbGpPWpGaD
Midazolam—SLC22A1—Neuronal System—BRAF—bone cancer	7.89e-05	0.00055	CbGpPWpGaD
Midazolam—GABRA1—Neuronal System—MDM2—bone cancer	7.72e-05	0.000538	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—NDUFA12—bone cancer	7.44e-05	0.000518	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	7.08e-05	0.000493	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—GSTP1—bone cancer	6.89e-05	0.00048	CbGpPWpGaD
Midazolam—SLC22A1—Neuronal System—MDM2—bone cancer	6.61e-05	0.00046	CbGpPWpGaD
Midazolam—CYP3A4—Biological oxidations—GSTP1—bone cancer	6.54e-05	0.000456	CbGpPWpGaD
Midazolam—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	6.45e-05	0.000449	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—NT5C3A—bone cancer	6.17e-05	0.000429	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—PTGS2—bone cancer	5.71e-05	0.000398	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	5.25e-05	0.000365	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	5.06e-05	0.000352	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—ENO2—bone cancer	4.95e-05	0.000345	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—ENO2—bone cancer	4.61e-05	0.000321	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—DHFR—bone cancer	4.59e-05	0.00032	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—NDUFA12—bone cancer	4.58e-05	0.000319	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	4.56e-05	0.000318	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—GNA11—bone cancer	4.29e-05	0.000299	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—DHFR—bone cancer	4.27e-05	0.000298	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—GNA11—bone cancer	3.99e-05	0.000278	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—CYP3A4—bone cancer	3.89e-05	0.000271	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—NT5C3A—bone cancer	3.8e-05	0.000265	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—ENO2—bone cancer	3.66e-05	0.000255	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—CYP3A4—bone cancer	3.62e-05	0.000252	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—ENO2—bone cancer	3.59e-05	0.00025	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.59e-05	0.00025	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—ENO2—bone cancer	3.58e-05	0.000249	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—PTGS2—bone cancer	3.57e-05	0.000249	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—DHFR—bone cancer	3.4e-05	0.000237	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—GSTP1—bone cancer	3.33e-05	0.000232	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—DHFR—bone cancer	3.33e-05	0.000232	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—DHFR—bone cancer	3.32e-05	0.000231	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—GNA11—bone cancer	3.17e-05	0.000221	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—GNA11—bone cancer	3.11e-05	0.000217	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—GNA11—bone cancer	3.1e-05	0.000216	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—GSTP1—bone cancer	3.1e-05	0.000216	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.01e-05	0.00021	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—CYP3A4—bone cancer	2.88e-05	0.0002	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—CYP3A4—bone cancer	2.82e-05	0.000196	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—CYP3A4—bone cancer	2.81e-05	0.000196	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—ENO2—bone cancer	2.7e-05	0.000188	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—DHFR—bone cancer	2.51e-05	0.000175	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—GSTP1—bone cancer	2.46e-05	0.000171	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—GSTP1—bone cancer	2.41e-05	0.000168	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—GSTP1—bone cancer	2.41e-05	0.000168	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—GNA11—bone cancer	2.34e-05	0.000163	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—CYP3A4—bone cancer	2.12e-05	0.000148	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—GSTP1—bone cancer	1.82e-05	0.000126	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—PTGS2—bone cancer	1.72e-05	0.00012	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—ENO2—bone cancer	1.66e-05	0.000116	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—PTGS2—bone cancer	1.6e-05	0.000112	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—DHFR—bone cancer	1.54e-05	0.000108	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—GNA11—bone cancer	1.44e-05	0.0001	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—PTGS2—bone cancer	1.28e-05	8.88e-05	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—PTGS2—bone cancer	1.25e-05	8.7e-05	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—PTGS2—bone cancer	1.25e-05	8.68e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—GSTP1—bone cancer	1.12e-05	7.79e-05	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—PTGS2—bone cancer	9.41e-06	6.55e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—PTGS2—bone cancer	5.79e-06	4.04e-05	CbGpPWpGaD
